Erythromycin OTC
Executive Summary
Will be the topic of a joint meeting of FDA's Dermatologic Drugs and Anti-Infective Drugs Advisory Committees Sept. 23. The committees are slated to discuss the potential for development of antibiotic resistance with OTC use of topical erythromycin to treat acne. The meeting will begin at 1 p.m. in conference rooms D&E at FDA's Parklawn building in Rockville, Md